Cardiff Oncology Appoints Mani Mohindru as President and CEO, Names Josh Muntner CFO and Ajay Aggarwal COO
Cardiff Oncology, Inc. has solidified its leadership team with the appointment of Mani Mohindru, PhD, as President and Chief Executive Officer, transitioning from her interim role. The company further strengthened its executive ranks with the addition of Josh Muntner as Chief Financial Officer, effective April 6, and Ajay Aggarwal, MD, MBA, as Chief Operating Officer, effective April 27. These strategic appointments aim to leverage extensive industry experience in finance, clinical development, and operations to advance the company's lead asset, onvansertib, particularly in its registrational program for first-line RAS-mutant metastatic colorectal cancer. The new leadership is expected to enhance Cardiff's ability to execute its strategic priorities and deliver potential new therapies to patients.
Key Highlights
- Mani Mohindru, PhD, has been appointed President and Chief Executive Officer, transitioning from her role as Interim CEO, and will continue as a Board member.
- Josh Muntner joins as Chief Financial Officer, effective April 6, bringing over 25 years of experience in capital markets strategy and financial operations, including raising $86 million in convertible financing at Imvax, Inc. and approximately $300 million in financings at Mesoblast Ltd.
- Ajay Aggarwal, MD, MBA, has been appointed Chief Operating Officer, effective April 27, with over 15 years of pharmaceutical industry experience in clinical development across respiratory, immunology, and oncology.
- The appointments are intended to build an experienced leadership team to advance onvansertib, Cardiff's lead asset, in its registrational program for first-line RAS-mutant metastatic colorectal cancer.
- CEO Mani Mohindru emphasized that building the right team is central to the company's strategy to deliver a potential new therapy to patients.